Today: 19 May 2026
British American Tobacco stock slips as Capital Group trims stake; buyback filing keeps BAT share price in focus
27 January 2026
1 min read

British American Tobacco stock slips as Capital Group trims stake; buyback filing keeps BAT share price in focus

London, Jan 27, 2026, 08:32 GMT — Regular session

British American Tobacco (BATS.L) shares slipped 0.2% to 4,299 pence at 0832 GMT, following Monday’s close at 4,308 pence. So far, the stock has fluctuated between 4,287 and 4,311 pence, with roughly 239,000 shares changing hands.

The drift follows a key disclosure revealing that Los Angeles-based The Capital Group Companies cut its voting stake in BAT to 18.869293% from 19.013003%. These filings highlight subtle shifts among major holders—signals traders watch closely for signs of supply and demand when the market is otherwise still.

BAT disclosed another chunk of buybacks under its ongoing programme, acquiring 101,395 ordinary shares on Jan. 23 at prices ranging from 4,295p to 4,339p. The company confirmed it plans to cancel these shares, which will leave 2.18 billion shares outstanding (excluding treasury stock) and roughly 133.0 million held in treasury.

The filings reveal a familiar tug-of-war behind this stock: steady corporate buying balanced by occasional selling from large institutions. Neither side moves the needle daily, but the balance becomes crucial when the market looks for clues on which way to go.

A buyback is simple: the company spends cash to repurchase its own shares, cutting the total share count. This can boost earnings per share and occasionally lift the stock price. Still, it doesn’t address the bigger issue facing the sector—how quickly the move away from cigarettes will drive sustainable growth.

BAT has already signaled investors to expect subdued growth in 2026, citing regulatory pressures and stiff competition in the U.S. vaping sector. Despite this, the company outlined a 1.3 billion pound buyback plan for next year. CEO Tadeu Marroco acknowledged early gains from cracking down on unregulated products but warned, “I’m trying to be cautious for 2026,” noting that roughly 70% of the U.S. vape market remains unregulated. At the time, Rae Maile from Panmure Liberum commented, “This is perhaps not quite what the share price needed.” Reuters

That’s the risk for holders: a stricter regulatory environment, slower growth in vaping and nicotine pouches, or a sharper retreat by major shareholders could overwhelm the steady stream of buybacks. In such a scenario, even small daily disclosures might take on outsized significance.

British American Tobacco is set to release its earnings on Feb. 12, per Investing.com’s earnings calendar. Investors will watch closely for any revisions to the 2026 guidance and updates on the speed of buybacks.

Stock Market Today

  • Top 5 Blue-Chip Stocks to Boost Portfolio Returns in 2026
    May 19, 2026, 9:58 AM EDT. The Dow Jones Industrial Average briefly surpassed 50,000 in May, highlighting positive momentum supported by its position above key moving averages. Analysts recommend five blue-chip stocks with strong Zacks Rank #2 (Buy) ratings to enhance portfolios in 2026: Cisco Systems (CSCO), Salesforce (CRM), Apple (AAPL), Visa (V), and Chevron (CVX). Cisco benefits from robust AI infrastructure demand and restructuring to focus on growth areas. Salesforce is expanding generative AI offerings through Einstein GPT and strategic investments. These stocks are favored for potential revenue and earnings growth amid evolving technological and economic trends.

Latest articles

Bakkt Up Early After Director Buys $4.85M in Shares

Bakkt Up Early After Director Buys $4.85M in Shares

19 May 2026
Bakkt shares jumped 14.2% to $9.96 in pre-market trading Tuesday after a filing showed director Michael Alfred’s vehicle bought $4.85 million in stock. SEC documents said Alfred acquired 585,000 shares last week via Alpine Fox LP. CEO Akshay Naheta exercised options for 33,557 shares at $10 each. Bakkt recently reported Q1 revenue of $243.6 million, down sharply from a year earlier.
Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

Relay Therapeutics Shares Rise In Pre-Market Ahead Of Key Drug Update

19 May 2026
Relay Therapeutics shares jumped 11.3% to $13.47 in premarket trading Tuesday after reporting a 60% volumetric response rate in 20 evaluable patients from its Phase 2 trial of zovegalisib for vascular anomalies. The company said 95% of patients saw some lesion reduction at 12 weeks. No patients discontinued due to adverse events. The regular Nasdaq session was set to open at 9:30 a.m. ET.

Popular

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.
SLB stock price edges higher near a fresh high as banks lift targets again
Previous Story

SLB stock price edges higher near a fresh high as banks lift targets again

Lloyds share price today: LLOY.L ticks higher as sanctions fine fades and results loom
Next Story

Lloyds share price today: LLOY.L ticks higher as sanctions fine fades and results loom

Go toTop